Alex Thurman Sells 625 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 625 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.15, for a total value of $61,968.75. Following the transaction, the chief financial officer directly owned 49,249 shares of the company’s stock, valued at approximately $4,883,038.35. This represents a 1.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Glaukos Stock Down 1.3%

GKOS stock opened at $100.81 on Friday. The company’s 50 day moving average price is $113.46 and its 200 day moving average price is $101.41. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of -30.92 and a beta of 0.70. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $130.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm had revenue of $143.12 million during the quarter, compared to analysts’ expectations of $132.16 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The firm’s revenue was up 35.6% compared to the same quarter last year. On average, equities research analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Glaukos

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in Glaukos by 183.4% in the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after acquiring an additional 1,953,578 shares during the last quarter. Primecap Management Co. CA grew its holdings in shares of Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Glaukos by 209.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after purchasing an additional 913,458 shares in the last quarter. Norges Bank acquired a new stake in shares of Glaukos during the second quarter worth about $76,314,000. Finally, Millennium Management LLC lifted its holdings in shares of Glaukos by 75.3% in the 4th quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock valued at $181,751,000 after purchasing an additional 691,289 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GKOS shares. Piper Sandler reiterated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. Stifel Nicolaus raised their price target on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. UBS Group upped their price objective on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Finally, Needham & Company LLC increased their price objective on Glaukos from $125.00 to $127.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.69.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.